for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

66.22USD

Change

-0.52(-0.78%)

Volume

282,635

Today's Range

66.07

 - 

66.82

52 Week Range

45.77

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
66.74
Open
66.57
Volume
282,635
3M AVG Volume
218.15
Today's High
66.82
Today's Low
66.07
52 Week High
68.34
52 Week Low
45.77
Shares Out (MIL)
2,260.00
Market Cap (MIL)
150,363.90
Forward P/E
10.42
Dividend (Yield %)
2.95

Next Event

Dividend For BMYMP.PK - 0.5000 USD

Latest Developments

更多

Bristol Myers Squibb Announces $2 Bln Incremental Share Repurchase Authorization

Avidity Biosciences Announces 2021 Pipeline Updates And Research Collaboration With Myokardia

Arsenalbio Announces Multi-Program Discovery Collaboration With Bristol Myers Squibb To Advance Next-Generation T Cell Therapies For Solid Tumors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

NEW YORK, NY

10016-8367

United States

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

David V. Elkins

Executive Vice President and Chief Financial Officer Member of the Leadership Team

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel

John E. Elicker

Executive Vice President of Investor Relations

Key Stats

1.89 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.8K

2018

22.6K

2019

26.1K

2020(E)

42.2K
EPS (USD)

2017

3.010

2018

3.980

2019

4.690

2020(E)

6.385
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.82
Price To Book (MRQ)
3.00
Price To Cash Flow (TTM)
16.72
Total Debt To Equity (MRQ)
89.61
LT Debt To Equity (MRQ)
82.47
Return on Investment (TTM)
-0.04
Return on Equity (TTM)
-0.03

Latest News

Latest News

FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs

Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a decision on an experimental blood cancer therapy that it acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.

Better-than-expected sales drive Bristol Myers earnings

Bristol Myers Squibb Co on Thursday posted better-than-expected third-quarter earnings, with most of its top-selling drugs outperforming Wall Street forecasts, as many Americans resumed routine medical care they had put off earlier in the coronavirus pandemic.

Bristol Myers psoriasis drug succeeds in late-stage study

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.

UPDATE 1-Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial.

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its blockbuster cancer immunotherapy, Opdivo, met the main goal of pathologic complete response, or the absence of cancer cells, in a late-stage study in patients with a type of lung cancer.

UPDATE 3-Bristol Myers expands heart drug business with $13 bln deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

Bristol-Myers to buy heart drugs developer MyoKardia for about $13 bln

U.S. drugmaker Bristol-Myers Squibb Co said on Monday it would buy heart drugs developer MyoKardia Inc for about $13 billion.

UPDATE 2-Bristol Myers lifts annual profit view on hopes of pickup in patient visits

Bristol Myers Squibb Co on Thursday raised its annual profit forecast as it predicted a recovery in sales of its hospital-administered drugs, which had taken a hit to demand as patients avoided doctors' offices due to the COVID-19 pandemic.

Bristol Myers lifts annual profit view on hopes of pickup in patient visits to doctors

Bristol Myers Squibb Co raised its annual profit forecast on Thursday on hopes of a recovery in demand for its hospital-administered drugs, which had dropped as patients stayed away from doctors' offices due to the COVID-19 pandemic.

Bristol Myers' treatment succeeds in late-stage bowel disease study

U.S. drugmaker Bristol Myers Squibb Co said on Tuesday its treatment Zeposia, which it gained through its $74 billion buyout of Celgene last year, met the main goals of a late-stage study testing it in patients with an inflammatory bowel disease.

UPDATE 2-U.S. FDA approves Bristol-Myers combo therapy for lung cancer

The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

U.S. FDA approves Bristol Myers' combo therapy for lung cancer

The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

U.S. FDA decides to not review Bristol Myers, bluebird therapy for multiple myeloma

The U.S. Food and Drug Administration decided to not review an experimental cancer therapy from Bristol Myers Squibb Co and partner bluebird bio Inc for patients with multiple myeloma, the companies said on Wednesday.

UPDATE 1-Bristol Myers to pay bluebird $200 mln for future royalties on cancer therapies

Bluebird bio Inc said on Monday Bristol Myers Squibb Co would give it a one-time payment of $200 million to buy out obligations for future royalties on sales outside the United States of two cancer therapies being developed by them.

Bristol Myers to pay $200 mln to Bluebird for royalty obligations

Bluebird bio Inc said on Monday partner Bristol Myers Squibb Co would pay $200 million to buy out future royalty obligations on sales of two therapies being developed by the companies.

UPDATE 1-Bristol Myers sees 2020 earnings holding despite coronavirus pandemic

Bristol Myers Squibb Co on Thursday reported better-than-expected first-quarter results, and said it still expects 2020 earnings within its previously forecast range despite the coronavirus pandemic that has savaged economies worldwide.

Bristol Myers sees 2020 earnings holding despite coronavirus pandemic

Bristol Myers Squibb Co on Thursday reported better-than-expected first-quarter results, and said it still expects 2020 earnings within its previously forecast range despite the coronavirus pandemic that has savaged economies worldwide.

UPDATE 1-U.S. FDA extends review of Bristol Myers' cancer therapy acquired in Celgene deal

Bristol Myers Squibb Co said on Wednesday the U.S. FDA has decided to extend the approval timeline for the drugmaker's experimental blood cancer therapy that was acquired as part of the $74 billion buyout of Celgene.

U.S. FDA extends review of Bristol Myers' cancer therapy acquired in Celgene deal

Bristol Myers Squibb said on Wednesday the U.S. drug regulator had extended the review of its experimental blood cancer therapy by three months after the drugmaker submitted additional information to the agency.

CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials

Bristol Myers Squibb Co said on Monday that its blockbuster cancer immunotherapy Opdivo performed well in two separate late-stage trials, prolonging survival in previously untreated patients with kidney cancer and lung cancer.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up